◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CRMD

CorMedix Inc (CRMD) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-25

CorMedix Inc (CRMD) operates in the BIOTECHNOLOGY industry and is headquartered in Parsippany, United States with about 191 employees. Its market capitalization is roughly $433 million. In the fiscal year ended 2025-12-31, CRMD reported $312M in revenue and $163M in net income.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Interactive charts & full statements → Open the CRMD valuation workbench →

CRMD Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Revenue	$462M	$312M	$43M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—
Gross Profit	$383M	$276M	$40M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	($1M)
Gross Margin %	82.8%	88.5%	92.7%	—	94.3%	22.0%	14.4%	-31.8%	7.7%	65.1%	-63.6%	-51.7%	-135.5%	-9980.2%	—	—	—	—	—
Operating Income (EBIT)	$217M	$150M	($22M)	($49M)	($31M)	($29M)	($27M)	($21M)	($27M)	($33M)	($25M)	($17M)	($9M)	($5M)	($3M)	($7M)	($9M)	($6M)	($5M)
Operating Margin %	46.9%	48.2%	-51.4%	—	-46819.9%	-15417.5%	-11378.4%	-7416.3%	-6250.4%	-9997.4%	-11048.8%	-7925.6%	-4703.3%	-245769.8%	—	—	—	—	—
Net Income	$187M	$163M	($18M)	($46M)	($30M)	($28M)	($22M)	($16M)	($27M)	($33M)	($25M)	($18M)	($20M)	($9M)	($3M)	($7M)	($11M)	($8M)	($9M)
Net Margin %	40.5%	52.3%	-41.2%	—	-45409.9%	-14774.7%	-9207.7%	-5801.3%	-6242.4%	-10023.4%	-10996.5%	-8655.4%	-10806.2%	-456654.9%	—	—	—	—	—
EBITDA	$250M	$168M	($19M)	($46M)	($30M)	($29M)	($27M)	($21M)	($27M)	($33M)	($25M)	($18M)	($20M)	($8M)	($3M)	($7M)	($8M)	($6M)	($4M)
Earnings Per Share (EPS)	$2.10	$2.03	$-0.30	$-0.91	$-0.74	$-0.75	$-0.77	$-0.68	$-1.51	$-2.99	$-3.25	$-2.90	$-4.77	$-3.30	$-1.50	$-2.94	$-5.76	$-47.40	$-53.42
Shares Outstanding (M)	92M	80M	59M	51M	40M	38M	29M	24M	18M	11M	8M	6M	4M	3M	2M	2M	2M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRMD Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$102M	$127M	$129M	$104M	$40M	$39M	$31M	$11M
Gross Profit	$77M	$105M	$107M	$93M	$38M	$37M	$30M	$11M
Gross Margin %	75.7%	82.5%	83.4%	89.3%	95.3%	95.9%	96.2%	94.0%
Operating Income (EBIT)	$43M	$64M	$59M	$51M	$20M	$20M	$13M	($3M)
Operating Margin %	42.1%	50.0%	46.0%	49.2%	49.2%	51.5%	41.4%	-28.7%
Net Income	$26M	$39M	$14M	$109M	$20M	$21M	$13M	($3M)
Net Margin %	25.5%	30.3%	10.9%	104.1%	49.9%	52.8%	43.1%	-24.2%
EBITDA	$57M	$66M	$69M	$57M	$21M	$21M	$14M	($3M)
Earnings Per Share (EPS)	$0.28	$0.42	$0.15	$1.26	$0.28	$0.30	$0.22	$-0.05
Shares Outstanding (M)	92M	93M	94M	86M	72M	69M	62M	59M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRMD Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Cash from Operations (CFO)	$254M	$175M	($51M)	($38M)	($24M)	($21M)	($22M)	($15M)	($24M)	($29M)	($22M)	($13M)	($6M)	($4M)	($2M)	($6M)	($4M)	($2M)	($4M)
Capital Expenditures (CapEx)	$4M	$2M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$250M	$173M	($51M)	($39M)	($25M)	($23M)	($22M)	($15M)	($24M)	($29M)	($22M)	($13M)	($6M)	($4M)	($2M)	($6M)	($4M)	($2M)	($4M)
FCF Margin %	54.1%	55.4%	-116.7%	—	-37573.5%	-11826.2%	-9229.7%	-5326.6%	-5525.7%	-8726.6%	-9961.5%	-5968.8%	-3352.9%	-182710.8%	—	—	—	—	—
Dividends Paid	—	—	—	—	—	—	—	—	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRMD Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$86M	$42M	$94M	$31M	$30M	$20M	($6M)	($14M)
Capital Expenditures (CapEx)	$1M	$1M	$2M	$1M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$86M	$42M	$93M	$30M	$30M	$20M	($6M)	($14M)
FCF Margin %	83.9%	32.7%	72.1%	29.1%	75.4%	50.5%	-18.0%	-119.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRMD Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Assets	$904M	$826M	$119M	$82M	$62M	$69M	$49M	$29M	$19M	$13M	$22M	$37M	$5M	$3M	$1M	$3M	$9M	$2M	$2M
Cash & Cash Equivalents	$257M	$146M	$41M	$44M	$43M	$53M	$42M	$17M	$18M	$10M	$8M	$12M	$4M	$2M	$1M	$2M	$8M	$2M	$1M
Total Liabilities	$443M	$421M	$34M	$12M	$7M	$6M	$5M	$6M	$14M	$6M	$4M	$3M	$1M	$7M	$2M	$1M	$2M	$17M	$14M
Total Debt (Short + Long-Term)	$145M	$146M	$0M	$0M	$0M	$0M	$0M	$0M	$6M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$14M	$12M
Total Shareholders' Equity	$461M	$405M	$85M	$70M	$55M	$63M	$44M	($195M)	($179M)	($152M)	$18M	$34M	$4M	($4M)	$0M	$1M	$7M	($15M)	($12M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRMD viewer.

Other Companies in BIOTECHNOLOGY

ARVN · Arvinas Inc — $464 million
EPRX · Eupraxia Pharmaceuticals Inc. Common Stock — $451 million
BLSM · BlossomHill Therapeutics, Inc. Common Stock — $437 million
PRTA · Prothena Corporation plc — $435 million
PROK · ProKidney Corp. — $427 million
CCCC · C4 Therapeutics Inc — $415 million
ASMB · Assembly Biosciences Inc — $410 million
ALLO · Allogene Therapeutics Inc — $408 million

← CRM All “C” companies CRMG →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.